In an immunology-related study, Seier and al. suggested exploring the use of H3K9 euchromatic histone-lysine methyltransferase (EHMT) inhibitors in combination with EZH2 inhibitors as an immunomodulation strategy for MNA NB treatment. This evidence concerns the gene EZH2 and neuroblastoma.